NCT00603980 - Staccato Alprazolam Abuse Liability | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

January 31, 2009

Study Completion Date

January 31, 2009

Conditions

Abuse Liability of Staccato Alprazolam

Interventions

DRUG

Inhaled placebo + oral placebo

Inhaled Staccato placebo + oral placebo

DRUG

Inhaled alprazolam 0.5 mg

Inhaled Staccato alprazolam 0.5 mg + oral placebo

DRUG

Inhaled alprazolam 1 mg

Inhaled Staccato alprazolam 1 mg + oral placebo

DRUG

Inhaled alprazolam 2 mg

Inhaled Staccato alprazolam 2 mg + oral placebo

DRUG

Oral alprazolam 1 mg

Oral alprazolam 1 mg + Inhaled placebo

DRUG

Oral alprazolam 2 mg

Oral alprazolam 2 mg + Inhaled placebo

DRUG

Oral alprazolam 4 m

Oral alprazolam 4 mg + Inhaled placebo

DRUG

Oral alprazolam 2 mg qualifying session

Qualifying session (2 mg oral alprazolam)

DRUG

Oral placebo qualifying session

Qualifying control session (oral placebo)

Trial Locations (1)

Johns Hopkins University School of Medicine, Baltimore